Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic cancer: Comparative effectiveness study.

被引：0
|
作者：
Cho, Jangho
Lim, Jae Yun
Cho, Jae Yong
机构：
[1] Gangnam Severance Hosp, Dept Med Oncol, Seoul, South Korea
[2] Gangnam Severance Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15132
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
    Zhu, Huayun
    Sun, Xiaofeng
    Pan, Xuan
    Wu, Pingping
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Gemcitabine plus capecitabine in elderly patients with advanced pancreatic cancer
    Vasiliki, Michalaki
    Andreas, Poydorou
    Antonios, Vezakis
    Georgios, Frangulidis
    Theodosios, Theodosopoulos
    Christos, Papadimitriou
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study.
    Song, HS
    Do, YR
    Chang, HM
    Lee, KH
    Kim, YH
    Hong, DS
    Cho, JY
    Lee, KE
    Kim, SY
    Ryu, MH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 343S - 343S
  • [44] Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer
    Park, Kwonoh
    Kim, Kyu-pyo
    Park, Seongjoon
    Chang, Heung-Moon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (01) : 13 - 20
  • [45] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Steven J. Cohen
    Mark M. Zalupski
    Manuel R. Modiano
    Paul Conkling
    Yehuda Z. Patt
    Peg Davis
    Robert T. Dorr
    Michelle L. Boytim
    Evan M. Hersh
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 287 - 294
  • [46] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Cohen, Steven J.
    Zalupski, Mark M.
    Modiano, Manuel R.
    Conkling, Paul
    Patt, Yehuda Z.
    Davis, Peg
    Dorr, Robert T.
    Boytim, Michelle L.
    Hersh, Evan M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 287 - 294
  • [47] A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer
    Gomez-Martin, C.
    Camara, J. C.
    Cortes, H.
    Jara, C.
    Gravalos, C.
    Rubio, B.
    Amador, M. L.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Gemcitabine and capecitabine improves survival in advanced pancreatic cancer patients
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (06) : 943 - 943
  • [49] Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer
    Hubner, Richard A.
    Worsnop, Fiona
    Cunningham, David
    Chau, Ian
    PANCREAS, 2013, 42 (03) : 511 - 515
  • [50] Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
    Davide Melisi
    Rocio Garcia-Carbonero
    Teresa Macarulla
    Denis Pezet
    Gael Deplanque
    Martin Fuchs
    Jorg Trojan
    Helmut Oettle
    Mark Kozloff
    Ann Cleverly
    Claire Smith
    Shawn T. Estrem
    Ivelina Gueorguieva
    Michael M. F. Lahn
    Al Blunt
    Karim A. Benhadji
    Josep Tabernero
    British Journal of Cancer, 2018, 119 : 1208 - 1214
12345